Aligos Therapeutics, Inc. (ALGS)

Market Cap	57.56M
Revenue (ttm)	15.53M
Net Income (ttm)	-87.68M
Shares Out	72.58M
EPS (ttm)	-1.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	239,212
Open	0.789
Previous Close	0.787
Day's Range	0.758 - 0.825
52-Week Range	0.539 - 1.380
Beta	2.34
Analysts	n/a
Price Target	n/a
Earnings Date	May 2, 2024

About ALGS

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I cli...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 66
• Stock Exchange: NASDAQ
• Ticker Symbol: ALGS

Financial Performance

In 2023, ALGS's revenue was $15.53 million, an increase of 11.66% compared to the previous year's $13.91 million. Losses were -$87.68 million, -8.71% less than in 2022.